Sandoz Submits BLA to US FDA for EG12014, a Proposed Biosimilar Trastuzumab to Treat HER2-positive Breast Cancer and Metastatic Gastric Cancers
Shots:
- The submission is based on analytical, pre-clinical, and clinical data to evaluate proposed biosimilar trastuzumab (150mg, IV) in breast & gastric cancer patients. Trastuzumab biosimilar is being developed by EirGenix
- Sandoz continues to build on generic and biosimilar oncology portfolios to increase patient access and contribute to the sustainability of healthcare systems. Trastuzumab is a mAb that was used to treat HER2-positive breast cancer and metastatic gastric cancers
- In Apr 2019, Sandoz entered into a license agreement with EirGenix where Sandoz get the right to commercialize EG12014 (biosimilar, trastuzumab) globally (Ex- China and Taiwan). EirGenix is responsible for the development and manufacturing of the product
Ref: Globe Newswire | Image: Sandoz
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
